MA24172A1 - Complexes d'inclusion de sels aryl-heterocycliques - Google Patents

Complexes d'inclusion de sels aryl-heterocycliques

Info

Publication number
MA24172A1
MA24172A1 MA24596A MA24596A MA24172A1 MA 24172 A1 MA24172 A1 MA 24172A1 MA 24596 A MA24596 A MA 24596A MA 24596 A MA24596 A MA 24596A MA 24172 A1 MA24172 A1 MA 24172A1
Authority
MA
Morocco
Prior art keywords
aryl
inclusion complexes
heterocyclic salt
salt inclusion
heterocyclic
Prior art date
Application number
MA24596A
Other languages
English (en)
Inventor
Charles Johnson Kevin
Kim Yesook
Mysore Shanker Ravi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA24172A1 publication Critical patent/MA24172A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Soil Conditioners And Soil-Stabilizing Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Machine Translation (AREA)
  • Seasonings (AREA)
MA24596A 1996-05-07 1997-05-06 Complexes d'inclusion de sels aryl-heterocycliques MA24172A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1920496P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
MA24172A1 true MA24172A1 (fr) 1997-12-31

Family

ID=21791976

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24596A MA24172A1 (fr) 1996-05-07 1997-05-06 Complexes d'inclusion de sels aryl-heterocycliques

Country Status (47)

Country Link
US (2) US6232304B1 (fr)
EP (1) EP0900088B1 (fr)
JP (1) JP3579060B2 (fr)
KR (1) KR20000010823A (fr)
CN (1) CN1216923A (fr)
AP (1) AP796A (fr)
AR (2) AR007002A1 (fr)
AT (1) ATE257714T1 (fr)
AU (1) AU713711B2 (fr)
BG (3) BG64474B1 (fr)
BR (1) BR9709213A (fr)
CA (1) CA2251912C (fr)
CO (1) CO4600677A1 (fr)
CZ (1) CZ297847B6 (fr)
DE (1) DE69727218T2 (fr)
DK (1) DK0900088T3 (fr)
DZ (1) DZ2220A1 (fr)
EA (1) EA001731B1 (fr)
EG (1) EG24135A (fr)
ES (1) ES2212809T3 (fr)
GE (1) GEP20074185B (fr)
GT (1) GT199700044A (fr)
HN (1) HN1997000039A (fr)
HR (1) HRP970237B1 (fr)
HU (1) HU222451B1 (fr)
ID (1) ID16866A (fr)
IL (1) IL126546A (fr)
IS (1) IS2524B (fr)
MA (1) MA24172A1 (fr)
ME (1) ME00880B (fr)
MY (1) MY121999A (fr)
NO (1) NO324373B1 (fr)
NZ (1) NZ332220A (fr)
OA (1) OA10907A (fr)
PL (1) PL189324B1 (fr)
PT (1) PT900088E (fr)
RS (1) RS49532B (fr)
SA (1) SA97180024B1 (fr)
SI (1) SI0900088T1 (fr)
SK (1) SK282032B6 (fr)
TN (1) TNSN97075A1 (fr)
TR (1) TR199802231T2 (fr)
TW (1) TW514529B (fr)
UA (1) UA57734C2 (fr)
UY (1) UY24544A1 (fr)
WO (1) WO1997041896A2 (fr)
ZA (1) ZA973874B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69730902T2 (de) * 1996-05-07 2006-02-23 Pfizer Inc. Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
JP4503724B2 (ja) * 1999-05-10 2010-07-14 栄研化学株式会社 ホタルルシフェリンの安定化方法
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
ATE428423T1 (de) * 2002-08-20 2009-05-15 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
OA12923A (en) * 2002-09-17 2006-10-13 Warner Lambert Co Heterocyclic substituted piperazines for the treatment of schizophrenia.
RU2310450C2 (ru) * 2002-10-25 2007-11-20 Пфайзер Продактс Инк. Новые депо-препараты для инъекций
CN1703198A (zh) * 2002-10-25 2005-11-30 辉瑞产品公司 呈混悬剂形式的芳基杂环活性物质的贮库制剂
EP1556086A2 (fr) * 2002-10-31 2005-07-27 Pfizer Products Inc. Conjugues ioniques polymeres solides et semi-solides
US20040147532A1 (en) * 2002-10-31 2004-07-29 Pfizer Inc Liquid conjugates of solid pharmaceuticals
MXPA03009945A (es) * 2002-11-05 2007-04-16 Lg Electronics Inc Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
CN1255105C (zh) * 2002-12-17 2006-05-10 上海医药工业研究院 齐拉西酮及其盐的水溶性包合物及其制备方法
WO2005016325A2 (fr) * 2003-06-03 2005-02-24 Teva Pharmaceutical Industries Ltd. Chlorhydrate de ziprasidone cristallin et ses procedes de preparation
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
WO2005055952A2 (fr) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions anticancereuses synergiques
EP1703898A2 (fr) * 2003-12-31 2006-09-27 Alpharma, Inc. Formulations de ziprasidone
SI21703A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia
EP1744750A2 (fr) 2004-05-06 2007-01-24 Sandoz AG Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
WO2006032957A1 (fr) * 2004-05-26 2006-03-30 Pfizer Products Inc. Procédé in vitro predictif
EP1753400A4 (fr) * 2004-06-11 2012-11-28 Reddys Lab Ltd Dr Forme de dosage de ziprasidone
CN101106972A (zh) * 2004-11-16 2008-01-16 伊兰制药国际有限公司 注射用纳米微粒奥氮平制剂
US20070032511A1 (en) * 2005-02-11 2007-02-08 Judith Aronhime Amorphous ziprasidone mesylate
EP1855651A4 (fr) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd Compositions nanoparticulaires de derives d'amide heterocyclique
WO2006098834A2 (fr) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Formes cristallines de mesylate de ziprasidone
US20060270685A1 (en) * 2005-03-14 2006-11-30 Judith Aronhime Anhydrous ziprasidone mesylate and a process for its preparation
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
BRPI0714886B8 (pt) 2006-07-10 2021-05-25 Paion Uk Ltd sais de benzodiazepina, seus usos e seus processos de preparação, e composição farmacêutica
US20080286373A1 (en) * 2007-05-18 2008-11-20 Palepu Nageswara R Ziprasidone formulations
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
WO2011148253A2 (fr) 2010-05-25 2011-12-01 Aurobindo Pharma Limited Formes posologiques solides d'antipsychotiques
EP2450039A1 (fr) 2010-11-08 2012-05-09 PAION UK Ltd. Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam)
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
CN102793701B (zh) * 2011-05-25 2014-12-17 上海医药工业研究院 卢拉西酮组合物
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
AR094963A1 (es) 2013-03-04 2015-09-09 Ono Pharmaceutical Co Reacción de oxidación excelente en el índice de conversión
US20250049709A1 (en) * 2021-12-11 2025-02-13 Beloteca, Inc. Ziprasidone formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
IT1196033B (it) 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
MX173362B (es) 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4883795A (en) 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1255462B (it) 1992-07-28 1995-11-02 Grazia Maffione Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
IT1263831B (it) 1993-01-29 1996-09-04 Paolo Chiesi Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
HU210922B (en) 1993-05-24 1995-09-28 Europharmaceuticals Sa Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them
IT1269578B (it) 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
BE1008307A3 (fr) 1994-06-16 1996-04-02 Europharmaceuticals Sa Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation.
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
DK0904273T3 (da) 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
DE69730902T2 (de) 1996-05-07 2006-02-23 Pfizer Inc. Verfahren zur Selektion eines Salzes zur Herstellung eines Inklusionskomplexes
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物

Also Published As

Publication number Publication date
CZ346198A3 (cs) 1999-09-15
CZ297847B6 (cs) 2007-04-11
AU713711B2 (en) 1999-12-09
RS49532B (sr) 2006-12-15
IS2524B (is) 2009-07-15
EP0900088B1 (fr) 2004-01-14
ME00880B (me) 2006-12-15
AR007002A1 (es) 1999-10-13
AP9700977A0 (en) 1997-07-31
AR045528A2 (es) 2005-11-02
TW514529B (en) 2002-12-21
EA199800910A1 (ru) 1999-04-29
AU1937297A (en) 1997-11-26
SI0900088T1 (en) 2004-04-30
DE69727218D1 (de) 2004-02-19
BG64475B2 (bg) 2005-04-30
BR9709213A (pt) 1999-08-10
DZ2220A1 (fr) 2002-12-03
US6399777B2 (en) 2002-06-04
NZ332220A (en) 2000-03-27
ES2212809T3 (es) 2004-08-01
EP0900088A2 (fr) 1999-03-10
NO985192D0 (no) 1998-11-06
UA57734C2 (uk) 2003-07-15
SK150498A3 (en) 2000-01-18
SK282032B6 (sk) 2001-10-08
WO1997041896A2 (fr) 1997-11-13
OA10907A (en) 2001-10-26
PL189324B1 (pl) 2005-07-29
CA2251912A1 (fr) 1997-11-13
ATE257714T1 (de) 2004-01-15
DE69727218T2 (de) 2004-11-18
JP3579060B2 (ja) 2004-10-20
ID16866A (id) 1997-11-20
JPH11509866A (ja) 1999-08-31
ZA973874B (en) 1998-11-06
HN1997000039A (es) 1997-06-26
IL126546A0 (en) 1999-08-17
US6232304B1 (en) 2001-05-15
US20010031756A1 (en) 2001-10-18
TR199802231T2 (xx) 1999-02-22
SA97180024B1 (ar) 2005-12-24
NO324373B1 (no) 2007-10-01
CN1216923A (zh) 1999-05-19
EG24135A (en) 2008-08-06
HUP9902799A2 (hu) 1999-12-28
GEP20074185B (en) 2007-08-10
UY24544A1 (es) 2000-09-29
EA001731B1 (ru) 2001-08-27
HRP970237A2 (en) 1998-12-31
WO1997041896A3 (fr) 1998-01-08
IL126546A (en) 2001-01-28
BG64475B1 (bg) 2005-04-30
MY121999A (en) 2006-03-31
PT900088E (pt) 2004-04-30
CO4600677A1 (es) 1998-05-08
AP796A (en) 1999-12-24
BG102894A (en) 1999-09-30
IS4880A (is) 1998-10-27
HRP970237B1 (en) 2002-04-30
CA2251912C (fr) 2003-06-03
GT199700044A (es) 1998-10-02
TNSN97075A1 (fr) 2005-03-15
NO985192L (no) 1998-11-06
HU222451B1 (hu) 2003-07-28
KR20000010823A (ko) 2000-02-25
DK0900088T3 (da) 2004-04-19
YU17297A (sh) 1999-12-27
PL329928A1 (en) 1999-04-26
BG64474B1 (bg) 2005-04-30
HUP9902799A3 (en) 2000-12-28

Similar Documents

Publication Publication Date Title
MA24172A1 (fr) Complexes d'inclusion de sels aryl-heterocycliques
NO985294D0 (no) Kontrastmidler
PT835256E (pt) Benzotriazois microbicidas
DE69713601D1 (de) Wasserlösliche tetrazoliumsalz-verbindungen
ID19801A (id) Turunan-turunan 5'-deoksi-sitidina
ATE215777T1 (de) Mikrobizide
NO995853L (no) Nytt salt
PT1060183E (pt) Derivados de 5'-desoxicitidina
BR9709521A (pt) "3-Cianoaril-pirazóis"
NO20005551D0 (no) 2"-deoksyhygromycinderivater
FR2758444B1 (fr) Boucles d'oreille
DK0827503T3 (da) Pyrrolidinylmethylindol-salt
DE69709700D1 (de) Kontrastmittel
NO996127L (no) 13-dihydro-3'-aziridino-antracykliner
KR970000122U (ko) 소금볶음로
BR9606017A (pt) "Enrotrilan"
ITCS970006V0 (it) "1 m"
KR960005231U (ko) 염전용 개량물꼬
FI2477U1 (fi) Uisteluvavat
BR9701198A (pt) Microbicidas
FI980765A0 (fi) Tillrinningsvask "skyddssystem"
SE9601982D0 (sv) Tifaret 6
BR9404821A (pt) Kit de segurança
KR970057015U (ko) 회전체 유희구
ITRA960003U1 (it) Free movement evolution - rm 01